Bio-Connect
IP analysis of 293T cell lysate using GTX54157 HELLS antibody. Antibody amount : 1microg / 200microg lysate Dilution : 1:1000
IP analysis of 293T cell lysate using GTX54157 HELLS antibody. Antibody amount : 1microg / 200microg lysate Dilution : 1:1000
IP analysis of 293T cell lysate using GTX54157 HELLS antibody. Antibody amount : 1microg / 200microg lysate Dilution : 1:1000

HELLS antibody

GTX54157
GeneTex
TargetHELLS
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    HELLS antibody
  • Delivery Days Customer
    7
  • Application Supplier Note
    WB: 1:500 - 1:2000. IHC-P: 1:50 - 1:200. IP: 1:50 - 1:200. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID3070
  • Target name
    HELLS
  • Target description
    helicase, lymphoid specific
  • Target synonyms
    ICF4; LSH; lymphoid-specific helicase; Nbla10143; PASG; proliferation-associated SNF2-like protein; SMARCA6; SWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 6
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9NRZ9
  • Protein Name
    Lymphoid-specific helicase
  • Scientific Description
    This gene encodes a lymphoid-specific helicase. Other helicases function in processes involving DNA strand separation, including replication, repair, recombination, and transcription. This protein is thought to be involved with cellular proliferation and may play a role in leukemogenesis. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jan 2014]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1. Schuller S et al., 2022 Jan 17, Cancers (Basel)
    Read more